Company Mateon Therapeutics, Inc. Other OTC
Equities
MATN
US57667K1097
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Vuong Trieu
CEO | Chief Executive Officer | 59 | 21/04/19 |
Director of Finance/CFO | 57 | 30/06/19 | |
Seymour H. Fein
CTO | Chief Tech/Sci/R&D Officer | 75 | 05/01/20 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 10/05/20 |
Saran Saund
PRN | Corporate Officer/Principal | 66 | 31/10/19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Steven King
BRD | Director/Board Member | 59 | 10/05/20 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 10/05/20 |
Vuong Trieu
CEO | Chief Executive Officer | 59 | 21/04/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 399,684,128 | 180,543,314 ( 45.17 %) | 0 | 45.17 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+18.15% | 124B | |
+18.02% | 111B | |
-12.75% | 23.17B | |
+5.07% | 22.94B | |
-39.94% | 17.42B | |
-9.86% | 17.42B | |
-14.97% | 16.9B | |
+2.80% | 13.71B | |
+27.39% | 11.82B |